| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 203.0 | 143.8 |
| Gross profit | 118.7 | 84.6 |
| Profit before tax | 24.1 | 23.0 |
| Net income | 17.1 | 24.3 |
| EPS (diluted, $ a share) | $0.46 | $0.66 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Net income, year on year | -29.8% |
|---|---|
| Revenue, year on year | +41.1% |
| Gross margin | 58.5% |
| Operating margin | 13.9% |
10-Q filed with the SEC, NASDAQ: TMDX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
TransMedics Group, Inc.: key numbers
- Share price
- $92.21Close, Nov 16
- Market cap
- $3.2B
- Shares outstanding
- 34.73MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Electromedical & Electrotherapeutic ApparatusSIC 3845
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from TransMedics Group, Inc.
All →TransMedics Group Director James R. Tobin Sells $380K of Stock
James R. Tobin, Director, sold 4,000 shares of TransMedics Group, Inc. at $94.98 a share, worth $380K in total on Nov 9, 2026. Shares held after the trade: 2,922 (-57.8%).
- Value
- $380K
- Shares
- 4,000
- Price
- $94.98
- Role
- Director
- Holding change
- -57.8%
- Trade date
- Nov 9, 2026
TransMedics Group Financial Results
TransMedics reported record third-quarter 2026 revenue of $203.0 million, a 41% increase year-over-year, driven by strong growth in both product and service revenue. The company achieved net income of $17.1 million and raised its full-year 2026 revenue guidance to a range of $764 million to $774 million.
“The third quarter of 2026 was the strongest in TransMedics’ history, with record revenue and record case volume. Importantly, we delivered these results despite typical third quarter seasonality and before any contribution from ENHANCE Part B or DENOVO.”
Waleed Hassanein, MD, President and Chief Executive Officer
“We enter 2027 with strong momentum and a robust set of growth catalysts. ENHANCE Heart Part B and DENOVO Lung target large, untapped heart and lung segments, with two shots on goal in each through OCS and CHOPS.”
Waleed Hassanein, MD, President and Chief Executive Officer
TransMedics Group Director David Weill Buys $109K of Stock
David Weill, Director, bought 1,336 shares of TransMedics Group, Inc. at $81.63 a share, worth $109K in total on Sep 11, 2026. Shares held after the trade: 16,392 (+8.9%).
- Value
- $109K
- Shares
- 1,336
- Price
- $81.63
- Role
- Director
- Holding change
- +8.9%
- Trade date
- Sep 11, 2026